Complement inhibitory therapeutics and xenotransplantation.
Nat Med
; 1(9): 967-8, 1995 Sep.
Article
en En
| MEDLINE
| ID: mdl-7585227
Once complement-mediated HAR has been inhibited, the full spectrum of cellular and antibody-mediated inflammatory and immune responses characteristic of acute and chronic rejection will need to be counter-manded. But the fact remains that if xenotransplantation is to become a clinical reality, a clinically relevant means of inhibiting complement activation will be required. Soluble complement receptor type 1 provides such a therapeutic option and an option where the dosing regimen is under the control of the physician and can be adjusted in response to the needs of the patient.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante Heterólogo
/
Proteínas Inactivadoras de Complemento
/
Refuerzo Inmunológico de Injertos
/
Activación de Complemento
/
Rechazo de Injerto
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Med
Asunto de la revista:
BIOLOGIA MOLECULAR
/
MEDICINA
Año:
1995
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos